Literature DB >> 24903655

[Recommendations for use of abatacept in patients with rheumatoid arthritis].

M Gaubitz1, K Krüger, J-P Haas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24903655     DOI： 10.1007/s00393-014-1373-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  40 in total

1.  Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.

Authors:  M Weinblatt; B Combe; A Covucci; R Aranda; J C Becker; E Keystone
Journal:  Arthritis Rheum       Date:  2006-09

2.  [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].

Authors:  B Manger; H Michels; H G Nüsslein; M Schneider; J Sieper
Journal:  Z Rheumatol       Date:  2007-02       Impact factor: 1.372

3.  Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis.

Authors:  Gregor Dueckers; Nihal Guellac; Martin Arbogast; Guenther Dannecker; Ivan Foeldvari; Michael Frosch; Gerd Ganser; Arnd Heiligenhaus; Gerd Horneff; Arnold Illhardt; Ina Kopp; Ruediger Krauspe; Barbara Markus; Hartmut Michels; Matthias Schneider; Wolfram Singendonk; Helmut Sitter; Marianne Spamer; Norbert Wagner; Tim Niehues
Journal:  Clin Immunol       Date:  2011-10-26       Impact factor: 3.969

4.  [Selective co-stimulation blockade. CTLA4-Ig (Abatacept)].

Authors:  R Alten; E Märker-Hermann
Journal:  Z Rheumatol       Date:  2010-09       Impact factor: 1.372

5.  Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.

Authors:  Joel M Kremer; Maxime Dougados; Paul Emery; Patrick Durez; Jean Sibilia; William Shergy; Serge Steinfeld; Elizabeth Tindall; Jean-Claude Becker; Tracy Li; Isaac F Nuamah; Richard Aranda; Larry W Moreland
Journal:  Arthritis Rheum       Date:  2005-08

6.  The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.

Authors:  Jeffrey R Curtis; Fenglong Xie; Lang Chen; John W Baddley; Timothy Beukelman; Kenneth G Saag; Claire Spettell; Raechele M McMahan; Joaquim Fernandes; Kevin Winthrop; Elizabeth Delzell
Journal:  Ann Rheum Dis       Date:  2011-05-17       Impact factor: 19.103

7.  Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.

Authors:  Teresa A Simon; Johan Askling; Diane Lacaille; Jarrod Franklin; Frederick Wolfe; Allison Covucci; Samy Suissa; Marc C Hochberg
Journal:  Arthritis Res Ther       Date:  2010-04-14       Impact factor: 5.156

8.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

Authors:  Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; Flavio Sztajnbok; Claudia Goldenstein-Schainberg; Morton Scheinberg; Immaculada Calvo Penades; Michael Fischbach; Javier Orozco; Philip J Hashkes; Christine Hom; Lawrence Jung; Loredana Lepore; Sheila Oliveira; Carol A Wallace; Leonard H Sigal; Alan J Block; Allison Covucci; Alberto Martini; Edward H Giannini
Journal:  Lancet       Date:  2008-07-14       Impact factor: 79.321

9.  Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis.

Authors:  Helen G Haggerty; Mark A Abbott; Timothy P Reilly; Deborah A DeVona; Carol R Gleason; Lee Tay; Robert Dodge; Richard Aranda
Journal:  J Rheumatol       Date:  2007-11-15       Impact factor: 4.666

10.  Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

Authors:  M Schiff; M Keiserman; C Codding; S Songcharoen; A Berman; S Nayiager; C Saldate; T Li; R Aranda; J-C Becker; C Lin; P L N Cornet; M Dougados
Journal:  Ann Rheum Dis       Date:  2007-11-29       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.